Omeprazole

Catalog No.S1389

For research use only.

Omeprazole is a proton pump inhibitor that blocks H(+)-K(+)-ATPase, used to treat dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger–Ellison syndrome.

Omeprazole Chemical Structure

CAS No. 73590-58-6

Selleck's Omeprazole has been cited by 6 Publications

Purity & Quality Control

Choose Selective Proton Pump Inhibitors

Other Proton Pump Products

Biological Activity

Description Omeprazole is a proton pump inhibitor that blocks H(+)-K(+)-ATPase, used to treat dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger–Ellison syndrome.
Targets
Proton pump [1]
()
H(+)-K(+)-ATPase [1]
()
In vitro

Omeprazole potently induces cytochrome P4501A1 mRNA expression in primary human hepatocytes, whereas this effect is not detected in mouse primary hepatocytes. Omeprazole induces transcription of reporter genes via the xenobiotic response element that is recognized by the ligand-activated dioxin receptor in human hepatoma cells. [1] Omeprazole causes a strong inhibition of basal natural killer (NK) activity in spleen cells (SC) from untreated CD2F1 mice. Omeprazole causes a rapid, strong effect on various types of cytotoxic lymphocytes ranging from cytotoxicity inhibition to irreversible cell damage. Omeprazole induces a significant inhibition of cytotoxic activity of all types of effector cells after 30 min incubation. [2] Omeprazole decreases the activation ofosteoclasts but increases that of osteoblasts in vitro, in part causing an osteopetrosis-like effect. [3]

In vivo Omeprazole blocks H(+)-K(+)-ATPase, thus enhances degeneration and macrophage-mediated elimination of parietal cells and also causes an increase in preparietal cell production. Omeprazole temporarily changes the dynamic features of parietal cells in the rabbit to make them die early and grow fast. [4]

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 69 mg/mL
(199.75 mM)
Ethanol 13 mg/mL
(37.63 mM)
Water Insoluble

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.

5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 345.42
Formula

C17H19N3O3S

CAS No. 73590-58-6
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05123820 Completed Drug: Treatment period A|Drug: Treatment period B Drug Drug Interaction|Healthy Idorsia Pharmaceuticals Ltd. November 13 2021 Phase 1
NCT04842981 Recruiting Drug: Tocilizumab|Drug: Sarilumab Arthritis Rheumatoid|Interaction University of Southern Denmark|Odense University Hospital|Hospital of South West Jutland|King Christian X´Hospital for Rheumatic Diseases|Sygehus Lillebaelt|Odense Patient Data Explorative Network May 25 2021 Phase 1|Phase 2
NCT04718740 Not yet recruiting Drug: fluzoparib Recurrent Ovarian Cancer Jiangsu HengRui Medicine Co. Ltd. March 2021 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Omeprazole | Omeprazole supplier | purchase Omeprazole | Omeprazole cost | Omeprazole manufacturer | order Omeprazole | Omeprazole distributor